相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Five Fralin Biomedical Research Institute at VTC faculty members received tenure during a June Virginia Tech Board of Visitors meeting, including four promotions to associate professor with tenure. - William "Matt" Howe's research has identified distinct neurochemical signatures differentiating Parkinson's disease from essential tremor, two of the most common neurological movement disorders. - Yassine Sassi's work on coding and non-coding RNAs and cyclic nucleotide pathways has generated mechanistic insights into pulmonary fibrosis, a disease that currently has no effective treatment. - Alexandra DiFeliceantonio and Jeffrey Stein co-direct the Center for Health Behaviors Research, studying ultra-processed foods and behavioral economics approaches to smoking and overeating.
- Carilion Clinic and Virginia Tech's Fralin Biomedical Research Institute are expanding clinical trials for theranostics, a precision medicine approach using radioactive isotopes for both imaging and therapy. - New trials will target brain and urologic cancers including glioblastoma and renal cell carcinoma, building on prior research that led to FDA-approved therapies Pluvicto and Lutathera. - The initiative aims to bring cutting-edge radiopharmaceutical treatments to underserved rural communities in Southwest Virginia, expanding access beyond major academic health centers. - Carilion now conducts approximately 150 clinical trials across more than 20 specialties as it prepares to open the Carilion Taubman Cancer Center in 2028.
• A recent study in JAMA Psychiatry suggests GLP-1 drugs like semaglutide may reduce alcohol-related issues in individuals with alcohol use disorder (AUD). • The Swedish study of 228,000 individuals with AUD, obesity, or type 2 diabetes found fewer alcohol-related hospitalizations among those taking GLP-1 agonists. • Experts suggest GLP-1 drugs may reduce cravings and the rewarding effects of alcohol, offering a potential new treatment avenue for AUD. • Further research is needed to understand the mechanisms and safety of GLP-1 drugs for AUD, especially in individuals without obesity or type 2 diabetes.
